141 related articles for article (PubMed ID: 17171705)
1. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice.
Richter F; Hamann M; Richter A
J Neurosci Res; 2007 Feb; 85(3):681-91. PubMed ID: 17171705
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
3. Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
Richter F; Hamann M; Richter A
Brain Res; 2008 Jan; 1188():148-56. PubMed ID: 18035334
[TBL] [Abstract][Full Text] [Related]
4. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
Inden M; Kitamura Y; Takeuchi H; Yanagida T; Takata K; Kobayashi Y; Taniguchi T; Yoshimoto K; Kaneko M; Okuma Y; Taira T; Ariga H; Shimohama S
J Neurochem; 2007 Jun; 101(6):1491-1504. PubMed ID: 17459145
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
[TBL] [Abstract][Full Text] [Related]
6. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
Nehru B; Verma R; Khanna P; Sharma SK
Brain Res; 2008 Mar; 1201():122-7. PubMed ID: 18308296
[TBL] [Abstract][Full Text] [Related]
7. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: a cautionary note.
Klein A; Gidyk DC; Shriner AM; Colwell KL; Tatton NA; Tatton WG; Metz GA
Behav Brain Res; 2011 Sep; 222(1):33-42. PubMed ID: 21419806
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
Nagel F; Bähr M; Dietz GP
Brain Res Bull; 2009 Jun; 79(5):303-9. PubMed ID: 19406215
[TBL] [Abstract][Full Text] [Related]
10. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging.
Phinney AL; Andringa G; Bol JG; Wolters ECh; van Muiswinkel FL; van Dam AM; Drukarch B
Parkinsonism Relat Disord; 2006 May; 12(4):228-38. PubMed ID: 16488175
[TBL] [Abstract][Full Text] [Related]
13. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH
Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture.
Radad K; Gille G; Rausch WD
Toxicol In Vitro; 2008 Feb; 22(1):68-74. PubMed ID: 17923380
[TBL] [Abstract][Full Text] [Related]
15. The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease.
Silvestrin RB; de Oliveira LF; Batassini C; Oliveira A; e Souza TM
J Neurosci Methods; 2009 Mar; 177(2):317-21. PubMed ID: 19026686
[TBL] [Abstract][Full Text] [Related]
16. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
17. Rotenone induces non-specific central nervous system and systemic toxicity.
Lapointe N; St-Hilaire M; Martinoli MG; Blanchet J; Gould P; Rouillard C; Cicchetti F
FASEB J; 2004 Apr; 18(6):717-9. PubMed ID: 14766796
[TBL] [Abstract][Full Text] [Related]
18. Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatum.
Dodd CA; Klein BG
Toxicol Ind Health; 2009 Feb; 25(1):25-39. PubMed ID: 19318502
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
Mulcahy P; Walsh S; Paucard A; Rea K; Dowd E
Neuroscience; 2011 May; 181():234-42. PubMed ID: 21277943
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity.
Luo C; Rajput AH; Akhtar S; Rajput A
Int J Mol Med; 2007 Mar; 19(3):517-21. PubMed ID: 17273802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
